Retinal biomarkers provide “insight” into cortical pharmacology and disease

Christine T.O. Nguyen, Flora Hui, Jason Charng, Shajan Velaedan, Anna K. van Koeverden, Jeremiah K.H. Lim, Zheng He, Vickie H.Y. Wong, Algis J. Vingrys, Bang V. Bui, Magnus Ivarsson

Research output: Contribution to journalReview articlepeer-review

32 Citations (Scopus)


The retina is an easily accessible out-pouching of the central nervous system (CNS) and thus lends itself to being a biomarker of the brain. More specifically, the presence of neuronal, vascular and blood-neural barrier parallels in the eye and brain coupled with fast and inexpensive methods to quantify retinal changes make ocular biomarkers an attractive option. This includes its utility as a biomarker for a number of cerebrovascular diseases as well as a drug pharmacology and safety biomarker for the CNS. It is a rapidly emerging field, with some areas well established, such as stroke risk and multiple sclerosis, whereas others are still in development (Alzheimer's, Parkinson's, psychological disease and cortical diabetic dysfunction). The current applications and future potential of retinal biomarkers, including potential ways to improve their sensitivity and specificity are discussed. This review summarises the existing literature and provides a perspective on the strength of current retinal biomarkers and their future potential.

Original languageEnglish
Pages (from-to)151-177
Number of pages27
JournalPharmacology and Therapeutics
Early online date5 Feb 2017
Publication statusPublished - Jul 2017
Externally publishedYes


  • Biomarker
  • Brain
  • Disease
  • Eye
  • Pharmacology
  • Retina


Dive into the research topics of 'Retinal biomarkers provide “insight” into cortical pharmacology and disease'. Together they form a unique fingerprint.

Cite this